Recombinant Human Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (RPN1)

What is the primary function of RPN1 in cellular biology?

RPN1 functions as a subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of defined glycans (specifically Glc₃Man₉GlcNAc₂ in eukaryotes) from the lipid carrier dolichol-pyrophosphate to asparagine residues within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains . This represents the first critical step in protein N-glycosylation. The process occurs cotranslationally as the OST complex associates with the Sec61 complex at the channel-forming translocon that mediates protein translocation across the endoplasmic reticulum (ER) . RPN1 acts as a receptor and regulator of protein translocation in the ER, helping guide and anchor nascent proteins to the ER membrane and facilitating their proper folding and glycan modification .

How is RPN1 structurally organized within the cell?

RPN1 is a 67 kDa membrane protein predominantly localized in the endoplasmic reticulum membrane . It contains specific domains that facilitate its interaction with other OST complex components and with nascent polypeptide chains emerging from the ribosome. Its orientation allows it to participate in the recognition of glycosylation sites and contribute to the enzymatic activity of the OST complex. The protein is encoded by the RPN1 gene in humans and has several synonyms including Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 67 kDa subunit, Ribophorin I, RPN-I, and Ribophorin-1 .

What experimental models are commonly used to study RPN1 function?

For in vitro studies of RPN1, researchers frequently use established cell lines such as:

• MCF7 (breast cancer cell line) for cancer-related studies

• MCF10A (normal human breast epithelial cell line) as a comparative control

Methodologically, RPN1 function can be studied through:

• RNA interference (shRNA, siRNA) for knockdown studies to assess the effects on cellular processes

• qRT-PCR for measuring RPN1 mRNA expression levels in tissues and cell lines

• Western blotting for protein expression analysis

• Immunohistochemistry for localization and expression in tissue samples

• Functional assays (proliferation, migration, invasion, and apoptosis) to assess phenotypic changes following RPN1 modulation

How does RPN1 expression differ between normal and cancerous tissues?

Multiple studies have demonstrated significant upregulation of RPN1 in cancerous tissues compared to normal tissues. Specifically:

• In breast cancer, RPN1 mRNA levels are significantly increased in tumor tissues compared to adjacent normal breast tissues (P < 0.05) .

• Similarly, breast cancer cell lines (MCF7) show significantly higher RPN1 expression compared to normal breast epithelial cells (MCF10A) .

• Pan-cancer analyses indicate RPN1 overexpression across multiple cancer types, suggesting it may serve as a common oncogenic factor .

This differential expression pattern is consistent across various malignancies and suggests RPN1 may play a functional role in tumorigenesis or cancer progression.

What signaling pathways does RPN1 interact with in cancer progression?

RPN1 has been demonstrated to interact with several critical oncogenic signaling pathways:

• PI3K/AKT/mTOR pathway: RPN1 knockdown attenuates the levels of phosphorylated PI3K, AKT, and mTOR relative to their total protein levels, indicating RPN1 activates this pro-survival and proliferative pathway in cancer cells .

• Endoplasmic reticulum (ER) stress response: RPN1 is associated with ER stress pathways involving key sensors including Activating Transcription Factor 6 (ATF6), Inositol-Requiring Enzyme 1α (IRE1α), and PKR-like ER Kinase (PERK) .

• Cell cycle regulation: Bioinformatic analyses and experimental validation have shown RPN1 is closely related to cell cycle processes, with knockdown inducing cellular senescence .

These interactions collectively contribute to RPN1's effects on cancer cell proliferation, survival, migration, and invasion.

What is the relationship between RPN1 and disulfidoptosis in cancer?

RPN1 has been identified as a key regulator associated with disulfidoptosis, a novel form of programmed cell death characterized by sensitivity to disulfide stress . Under glucose deprivation, cells with high expression of SLC7A11 exhibit rapid depletion of NADPH, leading to abnormal accumulation of disulfides such as cystine .

The connection between RPN1 and disulfidoptosis presents potential therapeutic opportunities:

• Targeting RPN1 could potentially modulate disulfidoptosis sensitivity in cancer cells

• This represents a promising avenue for exploiting cancer metabolic vulnerabilities

• The intricate relationship between this cell death process and the actin cytoskeleton suggests complex regulatory networks involving RPN1

Research in this area remains ongoing, with investigations into the mechanistic details of how RPN1 regulates this process across different cancer types.

What techniques can be used to effectively modulate RPN1 expression in experimental models?

For researchers investigating RPN1 function through expression modulation, several approaches have proven effective:

• RNA interference:

  • Short hairpin RNA (shRNA) for stable knockdown in long-term experiments

  • Small interfering RNA (siRNA) for transient knockdown studies

  • Design considerations should include targeting conserved regions of RPN1 mRNA with verified efficacy

• CRISPR-Cas9 gene editing:

  • For complete knockout or specific mutations in the RPN1 gene

  • Can be used to introduce tagged versions of RPN1 at endogenous loci

• Overexpression systems:

  • Plasmid vectors containing RPN1 cDNA with appropriate promoters

  • Inducible expression systems (e.g., Tet-On/Off) for temporal control

  • Viral vectors (lentivirus, adenovirus) for efficient transduction

• Pharmacological modulators:

  • Targeting RPN1 regulators like SP1, which has been shown to control RPN1 transcription

  • N-glycosylation inhibitors to study consequences of disrupting RPN1 function

Validation of modulation efficacy should combine qRT-PCR for mRNA expression , Western blotting for protein levels, and functional assays appropriate to the research question.

How can researchers assess the impact of RPN1 on tumor immune microenvironment?

Given RPN1's emerging role in immune modulation, researchers can employ these methodological approaches:

• Immune cell profiling in RPN1-manipulated models:

  • Flow cytometry to quantify tumor-infiltrating immune cell populations

  • Single-cell RNA sequencing to characterize immune cell states and heterogeneity

  • Multiplex immunohistochemistry/immunofluorescence for spatial context

• Correlation analyses with immune markers:

  • Assessment of relationships between RPN1 expression and:

    • Myeloid dendritic cells

    • Macrophages (particularly tumor-associated macrophages)

    • Tumor-associated fibroblasts

    • T-cell activity markers

• Immune checkpoint analysis:

  • Evaluate expression of immune checkpoint genes (e.g., SIGLEC7, SIRPA) in relation to RPN1 levels

  • Utilize the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm to predict how RPN1 affects T cell dysfunction and exclusion

• Co-culture experiments:

  • Establish co-culture systems with RPN1-modulated cancer cells and immune cells

  • Measure functional outcomes like T-cell activation, proliferation, and cytokine production

These approaches can elucidate RPN1's role in shaping the tumor immune microenvironment and potentially inform immunotherapy strategies.

What are the appropriate in vivo models for studying RPN1 function in cancer?

When designing in vivo experiments to investigate RPN1's role in cancer, researchers should consider:

• Xenograft models:

  • Subcutaneous implantation of RPN1-knockdown or overexpressing human cancer cell lines in immunodeficient mice

  • Orthotopic models for tissue-specific microenvironmental interactions

  • Patient-derived xenografts (PDXs) to maintain tumor heterogeneity

• Syngeneic models:

  • Using murine cancer cell lines with modulated Rpn1 expression in immunocompetent mice

  • Valuable for studying immune interactions when investigating RPN1's immunomodulatory effects

• Genetically engineered mouse models (GEMMs):

  • Conditional Rpn1 knockout or overexpression in specific tissues

  • Rpn1 modulation in established cancer GEMMs to assess its role in tumorigenesis or progression

• Monitoring approaches:

  • Tumor growth measurements (caliper, bioluminescence imaging)

  • Analysis of metastatic spread

  • Survival outcomes

  • Tissue collection for histology, RNA/protein expression, and immune profiling

Studies should adhere to ethical guidelines for animal research, as noted in the article which specified approval by the Laboratory Animal Ethics Committee .

How is RPN1 expression regulated at the genomic and epigenetic levels?

RPN1 expression is regulated through multiple complementary mechanisms:

• Copy Number Variation (CNV):

  • Copy number increases contribute to RPN1 upregulation in various cancers

  • This represents a genomic-level mechanism for increased expression

• DNA Methylation:

  • Decreased methylation of the RPN1 promoter region correlates with increased expression

  • This epigenetic modification enhances transcriptional accessibility

• Transcription Factor Regulation:

  • Specific Protein 1 (SP1) has been identified as a key transcription factor controlling RPN1 expression

  • Dual-luciferase reporter assays have confirmed SP1's direct regulatory role:

    • The RPN1 promoter was cloned into a firefly luciferase reporter vector

    • Co-transfection with SP1 expression vector demonstrated enhanced promoter activity

    • This interaction has been validated through normalized luciferase activity measurements

Understanding these regulatory mechanisms provides potential avenues for therapeutic intervention by targeting the factors controlling RPN1 expression rather than RPN1 itself.

What is the relationship between RPN1 and cellular senescence?

Research has revealed a significant connection between RPN1 and cellular senescence:

• Experimental evidence shows that RPN1 knockdown induces cellular senescence in cancer cells, marked by:

  • Increased senescence-associated biomarkers

  • Enhanced β-galactosidase activity (a classical senescence marker)

• Mechanistic connections:

  • RPN1's primary role in glycosylation modification links to senescence, as glycosylation has been extensively documented to influence senescence-related processes

  • Dysregulation of ER stress response, which RPN1 is involved in, can disrupt protein homeostasis and trigger senescence

  • Cell cycle regulation: RPN1 appears closely related to cell cycle processes, with its depletion leading to cell cycle arrest

• Cancer context:

  • Cellular senescence serves as an effective barrier to tumorigenesis

  • The presence of senescent cells in the tumor microenvironment is considered a hallmark of cancer

  • RPN1 may promote cancer progression partly by preventing premature senescence

This relationship provides a potential therapeutic angle, as inducing senescence through RPN1 modulation could be a strategy to limit cancer cell proliferation.

How does RPN1 expression correlate with clinical outcomes in cancer patients?

Analysis of clinical data has established significant correlations between RPN1 expression and patient outcomes:

These clinical correlations strengthen the rationale for investigating RPN1 as both a prognostic marker and a potential therapeutic target in cancer management.

What methodologies can be used to evaluate RPN1 as a therapeutic target?

Researchers exploring RPN1's potential as a therapeutic target can utilize these methodological approaches:

• Target validation studies:

  • Genetic approaches: RPN1 knockdown/knockout in diverse cancer cell lines to establish causality with cancer phenotypes

  • Pharmacological approaches: Small molecule inhibitors of RPN1 or its regulator SP1

  • Assessment of phenotypic endpoints: proliferation, migration, invasion, and apoptosis induction

• Combination therapy evaluation:

  • Testing RPN1 inhibition in combination with standard chemotherapies

  • Integration with immunotherapies, given RPN1's association with immune modulatory functions

  • Targeting parallel pathways, such as PI3K/AKT/mTOR inhibitors alongside RPN1 modulation

• Biomarker development:

  • Quantitative PCR-based assays for measuring RPN1 mRNA in clinical samples

  • Immunohistochemistry protocols for detecting RPN1 protein in tissue samples

  • Liquid biopsy approaches to detect circulating RPN1 or related markers

• Drug sensitivity prediction:

  • Leveraging data from resources such as the Genomics of Drug Sensitivity in Cancer database (GDSC)

  • Implementing computational approaches like "oncoPredict" to correlate RPN1 expression with response to various therapeutic agents

These methodological frameworks can guide systematic investigation of RPN1 as a therapeutic target across cancer types.

What are the key unsolved questions regarding RPN1 biology?

Despite significant advances in understanding RPN1's roles in normal physiology and cancer, several critical questions remain:

• Mechanistic details:

  • How does RPN1 precisely influence the PI3K/AKT/mTOR pathway activation?

  • What are the specific interaction partners mediating RPN1's effects on cancer cell behavior?

  • How does RPN1 contribute to regulating disulfidoptosis, and can this be therapeutically exploited?

• Cancer type specificity:

  • While RPN1 shows pan-cancer relevance, are there cancer-specific mechanisms of action?

  • Do different molecular subtypes of cancer show differential dependence on RPN1?

• Translational aspects:

  • Can RPN1 expression or activity be effectively targeted with small molecules or biologics?

  • What patient populations would most benefit from RPN1-targeted therapies?

  • How can RPN1 status be integrated with other biomarkers for patient stratification?

Addressing these questions will require interdisciplinary approaches combining molecular biology, biochemistry, immunology, and clinical research.

What novel technologies might advance our understanding of RPN1 function?

Emerging technologies that could significantly enhance RPN1 research include:

• Spatial omics approaches:

  • Spatial transcriptomics to map RPN1 expression patterns within the tumor microenvironment

  • Multiplexed imaging to correlate RPN1 with cellular phenotypes and neighboring cell types

• Advanced genetic manipulation:

  • CRISPR-based screens to identify synthetic lethal interactions with RPN1

  • Base editing or prime editing for precise modification of RPN1 regulatory elements

• Structural biology:

  • Cryo-electron microscopy of the OST complex containing RPN1

  • Structure-based drug design targeting RPN1 functional domains

• Systems biology:

  • Multi-omics integration (genomics, transcriptomics, proteomics, glycomics) to comprehensively map RPN1's role in cellular networks

  • Machine learning approaches to predict optimal RPN1-targeting strategies based on molecular profiles

• Improved models:

  • Organoid systems incorporating both cancer and stromal/immune components

  • Humanized mouse models for better assessment of immune interactions